<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Biodegradable polymer versus second-generation durable polymer drug-eluting stents in patients with coronary artery disease: A meta-analysis</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">James</forename><forename type="middle">J</forename><surname>Wu</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Sydney Medical School</orgName>
								<orgName type="institution">The University of Sydney</orgName>
								<address>
									<settlement>Camperdown</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Concord Repatriation General Hospital</orgName>
								<address>
									<settlement>Concord</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Joshua</forename><forename type="middle">A H</forename><surname>Way</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Sydney Medical School</orgName>
								<orgName type="institution">The University of Sydney</orgName>
								<address>
									<settlement>Camperdown</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><forename type="middle">Probal</forename><surname>Roy</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Sydney Medical School</orgName>
								<orgName type="institution">The University of Sydney</orgName>
								<address>
									<settlement>Camperdown</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Concord Repatriation General Hospital</orgName>
								<address>
									<settlement>Concord</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andy</forename><surname>Yong</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Sydney Medical School</orgName>
								<orgName type="institution">The University of Sydney</orgName>
								<address>
									<settlement>Camperdown</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Concord Repatriation General Hospital</orgName>
								<address>
									<settlement>Concord</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Harry</forename><surname>Lowe</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Sydney Medical School</orgName>
								<orgName type="institution">The University of Sydney</orgName>
								<address>
									<settlement>Camperdown</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Concord Repatriation General Hospital</orgName>
								<address>
									<settlement>Concord</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">|</forename><forename type="middle">Leonard</forename><surname>Kritharides</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Sydney Medical School</orgName>
								<orgName type="institution">The University of Sydney</orgName>
								<address>
									<settlement>Camperdown</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Concord Repatriation General Hospital</orgName>
								<address>
									<settlement>Concord</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">|</forename><surname>David Brieger</surname></persName>
							<email>david.brieger@health.nsw.gov.au</email>
							<affiliation key="aff0">
								<orgName type="department">Sydney Medical School</orgName>
								<orgName type="institution">The University of Sydney</orgName>
								<address>
									<settlement>Camperdown</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Concord Repatriation General Hospital</orgName>
								<address>
									<settlement>Concord</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Brieger</surname></persName>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Professor in Medicine</orgName>
								<orgName type="department" key="dep2">Sydney Medical School</orgName>
								<orgName type="institution">The University of Sydney</orgName>
								<address>
									<settlement>Camperdown</settlement>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Biodegradable polymer versus second-generation durable polymer drug-eluting stents in patients with coronary artery disease: A meta-analysis</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">D37C7AA4E779D96D30C077320541C94D</idno>
					<idno type="DOI">10.1002/hsr2.93</idno>
					<note type="submission">Received: 23 June 2018 Revised: 26 August 2018 Accepted: 4 September 2018</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:27+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>biodegradable polymer</term>
					<term>coronary artery disease</term>
					<term>drug-eluting stents</term>
					<term>durable polymer</term>
					<term>metaanalysis</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Aims: Biodegradable polymer drug-eluting stents (BP-DES) were developed in hopes of reducing the risk of stent thrombosis.</s><s>The comparison of this new stent platform with second-generation durable polymer drug-eluting stents (DP-DES) has not been well described.</s><s>We, therefore, performed a meta-analysis to evaluate the safety and efficacy profiles of BP-DES versus second-generation DP-DES in patients with coronary artery disease.</s></p><p><s>Methods and Results: Electronic database searches were conducted, from their dates of inception to June 2018, to identify randomized controlled trials (RCTs) comparing patients with either BP-DES or second-generation DP-DES.</s><s>Risk estimates were expressed as risk ratios (RRs) with 95% confidence intervals (CIs).</s><s>We also performed a landmark analysis beyond 1 year and sensitivity analyses based on different variables.</s><s>A total of 24,406 patients from 19 RCTs were included in the present metaanalysis.</s><s>There were no significant differences between BP-DES and second-generation DP-DES for the risks of definite or probable stent thrombosis (RR 0.88; 95% CI,</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1">| INTRODUCTION</head><p><s>Drug-eluting stents (DES) have revolutionized the treatment of coronary artery disease in patients undergoing percutaneous coronary intervention (PCI).</s><s>Advances in coronary stent technology have continually improved on patient outcomes through the refinement of design and component materials. <ref type="bibr" target="#b0">1</ref></s><s>These sequential stent platforms have included bare metal stents (BMS), durable polymer drug-eluting stents (DP-DES), and biodegradable polymer drug-eluting stents (BP-DES).</s><s>The first generation of DP-DES were introduced to reduce the risk of in-stent restenosis and subsequent target lesion revascularization associated with BMS. <ref type="bibr" target="#b1">2</ref> However, first-generation DP-DES were found to have an increased risk of very late stent thrombosis (&gt; 12 months) compared with BMS. <ref type="bibr" target="#b2">3</ref> This adverse event has been related to polymer-induced hypersensitivity reaction, incomplete strut re-endothelialization, stent malapposition, and accelerated neoatherosclerosis. <ref type="bibr" target="#b3">4</ref></s><s>Consequently, a second generation of DP-DES were developed, with novel anti-proliferative drugs, more biocompatible polymer coatings, and thinner metal alloy struts made possible by the use of cobalt-chromium or platinum-chromium in place of stainless steel. <ref type="bibr" target="#b4">5</ref></s><s>Second-generation DP-DES were shown to reduce the risk of very late stent thrombosis associated with first-generation DP-DES. <ref type="bibr" target="#b5">6</ref></s><s>wever, concerns regarding the potential thrombogenicity of the durable polymer coating have remained, resulting in recommendations for dual antiplatelet agents to be continued for longer periods following DP-DES implantation. <ref type="bibr" target="#b6">7</ref></s><s>-DES were developed in the hope of providing a similar safety profile to that of BMS (reduced risk of stent thrombosis), while maintaining the efficacy profile of DP-DES (reduced risk of target lesion revascularization).</s><s>The polymer coating of BP-DES degrades over two to nine months, and simultaneously releases controlled amounts of the anti-proliferative drug. <ref type="bibr" target="#b7">8</ref></s><s>The proposed benefit of BP-DES is the eventual absence of a foreign material in the vessel wall, in which there is a lower possibility for residual inflammation and, therefore, a reduced risk of very late stent thrombosis. <ref type="bibr" target="#b8">9</ref></s><s>There have been suggestions that BP-DES require a shorter duration of dual antiplatelet therapy (DAPT) than DP-DES. <ref type="bibr" target="#b9">10</ref></s><s>It is important to ensure that any potential safety benefits are not offset by the loss of efficacy (prevention of restenosis) through changes to the elution profile of the drug. <ref type="bibr" target="#b10">11</ref></s><s>erefore, we performed a meta-analysis of randomized controlled trial published to date to gain an evidence-based understanding of the safety and efficacy profiles of BP-DES versus second-generation DP-DES.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2">| METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.1">| Search strategy</head><p><s>Our meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. <ref type="bibr" target="#b11">12</ref></s><s>We conducted electronic database searches using Ovid Medline, PubMed, identify potentially relevant studies, we used the following keywords or MeSH terms: "randomized controlled trial", "drug-eluting stent", "durable polymer", "permanent polymer", "everolimus-eluting stent", "zotarolimus-eluting stent", "biodegradable polymer", "bioabsorbable polymer", "bioresorbable polymer", "biolimus-eluting stent", "sirolimuseluting stent", and "stent thrombosis".</s><s>The reference lists of retrieved articles were evaluated using the inclusion and exclusion criteria.</s></p><note type="other">Cochrane</note></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.2">| Selection criteria</head><p><s>The present meta-analysis included studies that had a randomized design.</s><s>We included studies comparing patients with either BP-DES or second-generation DP-DES (Table <ref type="table" target="#tab_1">1</ref>).</s><s>The BP-DES included biolimus-, everolimus-, and sirolimus-eluting stents.</s><s>The second-generation DP-DES included everolimus-and zotarolimus-eluting stents.</s></p><p><s>Studies evaluating sirolimus-and paclitaxel-eluting stents were not included, as these are first-generation DP-DES.</s><s>For duplicate studies, only the most recent reports with greatest number of patients and length of follow-up were included for quantitative assessment.</s><s>We limited the electronic database searches to studies involving human subjects.</s><s>We excluded conference abstracts, editorials, case reports, and review articles due to the possibility of publication bias and duplication of results.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.3">| Data extraction and critical appraisal</head><p><s>We extracted data from texts, tables, and figures.</s><s>Two independent investigators (JJW and JAW) reviewed each retrieved article for eligibility at the title or abstract level.</s><s>The senior author (DB) resolved any discrepancies between the two investigators by discussion and consensus.</s><s>Each included study was evaluated using the Cochrane Collaboration risk of bias tool <ref type="bibr" target="#b31">32</ref> (see supplementary table).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.4">| Outcomes</head><p><s>The primary outcome was definite or probable stent thrombosis, which was defined by the Academic Research Consortium (ARC). <ref type="bibr" target="#b32">33</ref></s><s>e secondary outcomes were myocardial infarction, cardiac death, all-cause death, target lesion revascularization, and target vessel revascularization.</s><s>All outcomes were extracted at the longest followup available and at 5 years of follow-up.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.5">| Statistical analysis</head><p><s>Risk ratios (RRs) with 95% confidence intervals (CIs) were used for summary statistics and risk estimates to compare patients receiving either BP-DES or second-generation DP-DES.</s><s>The Z test was used to derive P values.</s><s>The χ 2 test was used to assess heterogeneity between studies.</s><s>The I 2 statistic was used to assess total variation across studies, with values greater than 50% considered as significant heterogeneity. <ref type="bibr" target="#b31">32</ref></s><s>The Mantel-Haenszel fixed-effects model was used because there was no substantial heterogeneity between studies.</s><s>Risk of publication bias was assessed using funnel plots and statistical tests. <ref type="bibr" target="#b33">34</ref></s><s>We performed a landmark analysis beyond 1 year of followup to evaluate late safety and efficacy outcomes.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3">| RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1">| Study selection and patient population</head><p><s>Figure <ref type="figure">1</ref> illustrates the study selection process in the present metaanalysis.</s><s>We identified 1,298 references through electronic database searches.</s><s>After removing duplicate studies, we retrieved 1,126 potentially relevant articles.</s><s>After applying the inclusion and exclusion criteria, we included 19 RCTs <ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref> in the present meta-analysis, comprising data for 24,406 patients randomized to receive PCI with either BP-DES (n = 13,923) or second-generation DP-DES (n = 10,483).</s></p><p><s>Table <ref type="table" target="#tab_1">1</ref> summarizes the study characteristics of the included trials in the present meta-analysis.</s><s>Patients randomized to receive BP-DES were treated with either biolimus-, sirolimus-, or everolimus-eluting stent.</s><s>Patients randomized to receive second-generation DP-DES were treated with either everolimus-or zotarolimus-eluting stent.</s></p><p><s>The RCTs were assessed to be of high quality using the Cochrane Collaboration risk of bias tool. <ref type="bibr" target="#b34">35</ref></s><s>All trials had a multicenter design, with a median follow-up of 12 months.</s><s>The trials clearly identified the patient population, and defined the outcomes.</s><s>In four trials, <ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b20">21,</ref><ref type="bibr" target="#b25">26,</ref><ref type="bibr" target="#b29">30</ref> the main limitation was the lack of blinding of outcomes.</s><s>One trial <ref type="bibr" target="#b23">24</ref> included a third comparison arm of patients randomized to receive first-generation DP-DES.</s><s>Another trial <ref type="bibr" target="#b20">21</ref> included a third comparison arm of patients randomized to receive bioresorbable vascular scaffolds.</s></p><p><s>We excluded data from these third comparison arms because we deemed it irrelevant to our research question.</s><s>The funnel plots showed no evidence of publication bias (see supplementary figures).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2">| Patient and procedural characteristics</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3">| Safety and efficacy outcomes</head><p><s>Nineteen trials <ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref> reported definite or probable stent thrombosis (ST) in 24,274 patients.</s><s>There was no significant difference between patients with BP-DES and those with second-generation DP-DES for the risk of definite or probable ST (1.0% vs 1.2%; RR 0.88; 95% CI, 0.69-1.12;</s><s>P = 0.29; I 2 = 0%; Figure <ref type="figure">2</ref>).</s><s>Nineteen trials <ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref> reported myocardial infarction (MI) in 24,275 patients.</s><s>There was no significant difference between patients with BP-DES and those with secondgeneration DP-DES for the risk of MI (4.6% vs 4.7%; RR 0.97; 95% CI, 0.86-1.09;</s><s>P = 0.59; I 2 = 0%; Figure <ref type="figure">3</ref>).</s><s>Nineteen trials <ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref> reported cardiac death in 24,279 patients.</s><s>There was no significant difference between patients with BP-DES and those with second-generation DP-DES for the risk of cardiac death (2.4% vs 2.2%; RR 1.08; 95% CI, 0.92-1.28;</s><s>P = 0.34; I 2 = 0%; Figure <ref type="figure">4</ref>).</s><s>Eighteen trials <ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref> reported all-cause death in 24,084 patients. There</s><s>was no significant difference between patients with BP-DES and those with second-generation DP-DES for the risk of all-cause death (5.5% vs 5.4%; RR 1.02; 95% CI, 0.91-1.13;</s><s>P = 0.77; I 2 = 0%; Figure <ref type="figure">5</ref>).</s><s>Seventeen trials <ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref><ref type="bibr" target="#b30">[31]</ref> reported target lesion revascularization (TLR) in 22,543 patients.</s><s>There was no significant difference between patients with BP-DES and those with second-generation DP-DES for the risk of TLR (5.5% vs 5.2%; RR 1.05; 95% CI, 0.94-1.17;</s><s>P = 0.38; I 2 = 22%; Figure <ref type="figure">6</ref>).</s><s>Seventeen trials <ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref><ref type="bibr" target="#b20">[21]</ref><ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b24">[25]</ref><ref type="bibr" target="#b25">[26]</ref><ref type="bibr" target="#b26">[27]</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref> reported target vessel revascularization (TVR) in 21,999 patients.</s><s>There was no significant difference between patients with BP-DES and those with second-generation DP-DES for the risk of TVR (6.3% vs 6.3%; RR 1.05; 95% CI, 0.95-1.16;</s><s>P = 0.36; I 2 = 4%).</s></p><p><s>Table <ref type="table" target="#tab_3">3</ref> summarizes the safety and efficacy outcomes in different subgroups.</s><s>At 5 years of follow-up, there were no significant differences between patients with BP-DES and those with secondgeneration DP-DES for the risks of definite or probable ST, MI, cardiac death, all-cause death, TLR, and TVR (all P &gt; 0.05).</s><s>Similarly, our landmark analysis beyond 1 year of follow-up showed no significant differences between patients with BP-DES and those with secondgeneration DP-DES for all outcomes (all P &gt; 0.05).</s><s>Our sensitivity analysis based on BP-DES anti-proliferative drug (biolimus, everolimus, or sirolimus), DP-DES anti-proliferative drug (everolimus or zotarolimus), and duration of DAPT (6 months or 12 months) showed no significant differences between patients with BP-DES and those with second-generation DP-DES for all outcomes (all P &gt; 0.05).</s><s>The potential chronic inflammatory stimulus of the polymer coating ultimately led to the design of BP-DES in an attempt to reduce the risk of very late ST associated with DP-DES. <ref type="bibr" target="#b4">5</ref></s><s>The biodegradable nature of the polymer coating was thought to improve vascular healing response by reducing platelet aggregation and inflammatory   cell adhesion. <ref type="bibr" target="#b36">37</ref></s><s>However, this benefit was not realized in the present meta-analysis, which found no significant difference between BP-DES and second-generation DP-DES for the risk of definite or probable ST at 5 years of follow-up and on landmark analysis beyond 1 year of follow-up.</s><s>Similarly, a meta-analysis 38 of 13,480 patients showed no significant difference between BP-DES and first-generation DP-DES for the risk of definite or probable ST.</s><s>Some animal studies <ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b39">40</ref> demonstrated higher rates of inflammation associated with biodegradable polymers than durable polymers.</s><s>The attenuated benefit of BP-DES may be explained by this chronic inflammatory process associated with the degradation of the polymer coating.</s></p><p><s>The polymer coatings in different BP-DES dissolve at various rates, including 2 months for the Synergy everolimus-eluting stent (Boston Scientific, Natick, Massachusetts) and 9 months for the Nobori biolimus-eluting stent (Terumo, Shibuya, Tokyo), which might result in differing safety and efficacy profiles. <ref type="bibr" target="#b40">41</ref></s><s> BP-DES have been proposed to allow a shorter duration of DAPT due to improved vascular healing response in the stented segment. <ref type="bibr" target="#b42">43</ref></s><s> light of this theoretical advantage, BP-DES might offer a valuable therapeutic option to patients at high risk of bleeding or deemed unsuitable for prolonged used of DAPT, with minimal penalty in terms of safety and efficacy outcomes. <ref type="bibr" target="#b43">44</ref></s><s>In fact, the latest American College of Cardiology/American Heart Association (ACC/AHA) guidelines <ref type="bibr" target="#b44">45</ref> have shortened the recommended duration of DAPT from 12 months to 6 months following DES implantation.</s><s>Our sensitivity analysis based on duration of DAPT (6 months or 12 months) demonstrated equivalent rates of safety and efficacy outcomes between BP-DES and second-generation DP-DES, thereby supporting the ACC/AHA recommendations for DES, with no additional advantages realized with BP-DES.</s><s>The degradation of the polymer coating was thought to reduce the risk of very late ST in patients with BP-DES compared to those with DP-DES. <ref type="bibr" target="#b8">9</ref></s><s>However, this benefit was not realized in our sensitivity analysis, which found no significant differences in safety and efficacy outcomes between the two stent platforms at 5 years of follow-up and on landmark analysis beyond 1 year of follow-up.</s></p><p><s>We reduced the risk of bias by combining data from RCTs only.</s><s>The number of patients in each comparison arm would have increased if we used less stringent inclusion and exclusion criteria.</s><s>However, the absence of significant heterogeneity across the included studies suggested that risk estimates were unlikely to change by the inclusion of observational studies.</s><s>There were limitations in our meta-analysis that should be acknowledged.</s><s>As with any meta-analysis, our study was based on aggregate data and, therefore, shared the possible limitations of the original studies, which in many cases compared stents with different anti-proliferative drugs, durations of DAPT, and lengths of follow-up.</s></p><p><s>We attempted to address this source of bias by performing sensitivity analyses based on these variables.</s><s>The present meta-analysis summarized the results of 19 RCTs, with a median follow-up of 12 months.</s></p><p><s>Extension of follow-up beyond this time point in the original studies remains crucial to assessing late safety and efficacy outcomes of BP-DES once the polymer has been completely degraded.</s><s>Further RCTs with abbreviated duration of DAPT and long-term follow-up in larger number of patients are necessary to assess the purported benefits of BP-DES.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5">| CONCLUSIONS</head><p><s>In summary, our findings demonstrated that BP-DES have similar safety and efficacy profiles to second-generation DP-DES, with comparable rates of definite or probable ST.</s><s>Other safety and efficacy outcomes were equivalent between the two stent platforms.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>FUNDING</head><p><s>None declared.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>Central Register of Controlled Trials (CCTR), Cochrane Database of Systematic Reviews (CDSR), American College of Physicians (ACP) Journal Club, and Database of Abstracts of Reviews of Effectiveness (DARE) from their dates of inception to June 2018.</s><s>To</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>To assess the extent to which variables might influence the risk estimate of each outcome, we performed sensitivity analyses based on different variables: BP-DES anti-proliferative drug (biolimus, everolimus, or sirolimus); DP-DES anti-proliferative drug (everolimus or zotarolimus); and duration of DAPT (6 months or 12 months).</s><s>We conducted statistical analyses using RevMan Version 5.3 (The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen).</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>FIGURE 2 FIGURE 3 FIGURE 4 FIGURE 5 FIGURE 6</head><label>23456</label><figDesc><div><p><s>FIGURE 2 Risk of definite or probable stent thrombosis.</s><s>BP-DES = biodegradable polymer drug-eluting stents.</s><s>DP-DES = durable polymer drug-eluting stents.</s><s>M-H = Mantel-Haenszel</s></p></div></figDesc><graphic coords="5,112.48,46.49,370.36,187.09" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head></head><label></label><figDesc><div><p><s>Values are risk ratio (95% confidence interval); BP-DES = biodegradable polymer drug-eluting stent; DAPT = dual antiplatelet therapy; MI = myocardial infarction; PCI = percutaneous coronary intervention; ST = stent thrombosis; TLR = target lesion revascularization; TVR = target vessel revascularization.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>FIGURE 7</head><label>7</label><figDesc><div><p><s>FIGURE 7 Risk of target vessel revascularization.</s><s>BP-DES = biodegradable polymer drug-eluting stents.</s><s>DP-DES = durable polymer drug-eluting stents.</s><s>M-H = Mantel-Haenszel</s></p></div></figDesc><graphic coords="7,112.48,46.49,370.36,174.95" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="4,54.77,46.49,313.88,337.83" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="6,112.59,46.49,370.38,188.05" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="6,112.48,298.94,370.36,179.43" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="6,112.37,544.37,370.71,180.96" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 2</head><label>2</label><figDesc></figDesc><table><row><cell>Overall, the two comparison groups had similar proportions of male</cell></row><row><cell>patients and with diabetes mellitus, hypertension, hyperlipidemia, cur-</cell></row><row><cell>rent smoking, previous myocardial infarction, previous procedure (PCI</cell></row><row><cell>or coronary artery bypass grafting), clinical presentation (stable/unsta-</cell></row><row><cell>ble angina or non-/ST-elevation myocardial infarction), and target ves-</cell></row><row><cell>sel location (left anterior descending, left circumflex, or right coronary</cell></row><row><cell>artery) (all P &gt; 0.05). However, the proportion of patients with previ-</cell></row><row><cell>ous PCI was significantly higher in those receiving BP-DES than those</cell></row><row><cell>receiving second-generation DP-DES (26.4% vs 26.2%; P = 0.03).</cell></row></table><note><p><s>summarizes the baseline characteristics of the included trials in the present meta-analysis.</s><s>The enrolled patients had a weighted mean age of 64.7 ± 10.7 years for those receiving BP-DES and 64.9 ± 10.6 years for those receiving second-generation DP-DES.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>TABLE 1</head><label>1</label><figDesc><div><p><s>Study characteristics</s></p></div></figDesc><table><row><cell>Patient (n)</cell></row></table><note><p><s>BP-DES = biodegradable polymer drug-eluting stents; DAPT = dual antiplatelet therapy; DP-DES = durable polymer drug-eluting stents.FIGURE 1 Flow diagram of study selection process</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>TABLE 2 Baseline characteristics Baseline characteristic BP-DES DP-DES RR or WMD (95% CI) P Value a</head><label>2</label><figDesc></figDesc><table><row><cell>Age (years)</cell><cell>64.7 ± 10.7</cell><cell>64.9 ± 10.6</cell><cell>−0.14 (−0.42 to 0.13)</cell><cell>0.30</cell></row><row><cell>Male</cell><cell>10,385/13,923 (74.6)</cell><cell>7,928/10,483 (75.6)</cell><cell>0.99 (0.98 to 1.00)</cell><cell>0.17</cell></row><row><cell>Diabetes mellitus</cell><cell>3,575/13,923 (25.7)</cell><cell>2,720/10,482 (25.9)</cell><cell>1.02 (0.97 to 1.06)</cell><cell>0.47</cell></row><row><cell>Hypertension</cell><cell>8,900/13,923 (63.9)</cell><cell>6,841/10,483 (65.3)</cell><cell>1.00 (0.98 to 1.02)</cell><cell>0.76</cell></row><row><cell>Hyperlipidemia</cell><cell>7,470/12,128 (61.6)</cell><cell>6,060/9,571 (63.3)</cell><cell>1.00 (0.98 to 1.02)</cell><cell>0.70</cell></row><row><cell>Current smoking</cell><cell>3,607/13,693 (26.3)</cell><cell>2,719/10,297 (26.4)</cell><cell>1.00 (0.96 to 1.05)</cell><cell>0.89</cell></row><row><cell>Previous MI</cell><cell>2,837/12,977 (21.9)</cell><cell>2,009/9,545 (21.0)</cell><cell>1.02 (0.97 to 1.08)</cell><cell>0.38</cell></row><row><cell>Previous PCI</cell><cell>3,224/12,204 (26.4)</cell><cell>2,501/9,553 (26.2)</cell><cell>1.05 (1.01 to 1.10)</cell><cell>0.03</cell></row><row><cell>Previous CABG</cell><cell>866/11,257 (7.7)</cell><cell>648/8,971 (7.2)</cell><cell>0.98 (0.89 to 1.07)</cell><cell>0.62</cell></row><row><cell>Clinical presentation</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Stable angina</cell><cell>5,657/12,418 (45.6)</cell><cell>4,383/9,237 (47.5)</cell><cell>0.99 (0.96 to 1.02)</cell><cell>0.44</cell></row><row><cell>Unstable angina</cell><cell>2,017/10,064 (20.0)</cell><cell>1,475/7,410 (19.9)</cell><cell>1.02 (0.97 to 1.08)</cell><cell>0.46</cell></row><row><cell>NSTEMI</cell><cell>2,550/9,736 (26.2)</cell><cell>1,879/7,045 (27.7)</cell><cell>0.99 (0.94 to 1.04)</cell><cell>0.70</cell></row><row><cell>STEMI</cell><cell>2,056/9,491 (21.7)</cell><cell>1,372/6,790 (20.2)</cell><cell>1.04 (0.98 to 1.11)</cell><cell>0.21</cell></row><row><cell>Target vessel location</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>LAD</cell><cell>6,562/14,704 (44.6)</cell><cell>5,147/11,589 (44.4)</cell><cell>1.02 (0.99 to 1.05)</cell><cell>0.16</cell></row><row><cell>LCx</cell><cell>3,590/14,704 (24.4)</cell><cell>2,905/11,589 (25.1)</cell><cell>0.97 (0.93 to 1.01)</cell><cell>0.14</cell></row><row><cell>RCA</cell><cell>4,825/14,704 (32.8)</cell><cell>3,827/11,589 (33.0)</cell><cell>1.00 (0.97 to 1.04)</cell><cell>0.88</cell></row></table><note><p><s>Values are n/N (%) or mean ± SD; BP-DES = biodegradable drug-eluting stents; CABG = coronary artery bypass grafting; DP-DES = durable polymer drugeluting stents; LAD = left anterior descending artery; LCx = left circumflex artery; MI = myocardial infarction; NSTEMI = non-ST-elevation myocardial infarction; PCI = percutaneous coronary intervention; RCA = right coronary artery; RR = risk ratio; STEMI = ST-elevation myocardial infarction; WMD = weighted mean difference; a P value for Z test.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>TABLE 3</head><label>3</label><figDesc><div><p><s>Safety and efficacy outcomes</s></p></div></figDesc><table><row><cell></cell><cell>Definite or</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Analysis</cell><cell>probable ST</cell><cell>MI</cell><cell>Cardiac death</cell><cell>All-cause death</cell><cell>TLR</cell><cell>TVR</cell></row><row><cell>Outcomes at longest</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>follow-up</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Outcomes at 5 years</cell><cell cols="6">0.92 (0.57 to 1.49) 1.10 (0.89 to 1.35) 1.07 (0.83 to 1.38) 1.03 (0.88 to 1.20) 1.06 (0.91 to 1.24) 1.16 (0.98 to 1.37)</cell></row><row><cell>Landmark analysis beyond</cell><cell cols="6">1.24 (0.57 to 2.74) 1.07 (0.79 to 1.45) 1.10 (0.83 to 1.46) 0.92 (0.76 to 1.11) 1.17 (0.94 to 1.45) 1.21 (0.98 to 1.51)</cell></row><row><cell>1 year</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Sensitivity analysis</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>BP-DES anti-</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>proliferative drug</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Biolimus</cell><cell cols="6">1.05 (0.71 to 1.55) 1.05 (0.89 to 1.23) 1.19 (0.96 to 1.49) 0.99 (0.86 to 1.13) 1.04 (0.89 to 1.21) 1.11 (0.98 to 1.26)</cell></row><row><cell>Everolimus</cell><cell cols="6">0.72 (0.29 to 1.78) 1.02 (0.74 to 1.41) 0.88 (0.45 to 1.74) 1.18 (0.72 to 1.94) 1.02 (0.67 to 1.57) 0.82 (0.58 to 1.14)</cell></row><row><cell>Sirolimus</cell><cell cols="6">0.80 (0.58 to 1.09) 0.84 (0.70 to 1.01) 0.96 (0.74 to 1.26) 1.05 (0.88 to 1.25) 1.07 (0.90 to 1.26) 0.95 (0.78 to 1.16)</cell></row><row><cell>DP-DES anti-</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>proliferative drug</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Everolimus</cell><cell cols="6">0.83 (0.63 to 1.10) 0.95 (0.83 to 1.08) 1.04 (0.85 to 1.28) 1.06 (0.93 to 1.22) 1.07 (0.94 to 1.21) 1.07 (0.94 to 1.20)</cell></row><row><cell>Zotarolimus</cell><cell cols="6">0.93 (0.55 to 1.57) 1.04 (0.80 to 1.34) 1.19 (0.84 to 1.68) 1.00 (0.80 to 1.25) 0.94 (0.74 to 1.21) 0.98 (0.79 to 1.21)</cell></row><row><cell>Duration of DAPT</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>6 months</cell><cell cols="6">0.84 (0.51 to 1.39) 1.02 (0.82 to 1.27) 0.95 (0.69 to 1.30) 0.99 (0.81 to 1.21) 0.98 (0.81 to 1.18) 0.85 (0.67 to 1.08)</cell></row><row><cell>12 months</cell><cell cols="6">0.83 (0.64 to 1.09) 0.95 (0.82 to 1.11) 1.10 (0.90 to 1.34) 1.05 (0.92 to 1.19) 1.11 (0.96 to 1.27) 1.08 (0.94 to 1.23)</cell></row></table><note><p><s>0.88 (0.69 to 1.12) 0.97 (0.86 to 1.09) 1.08 (0.92 to 1.28) 1.02 (0.91 to 1.13) 1.05 (0.94 to 1.17) 1.05 (0.95 to1.16)</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" n="2">of 10 WU ET AL.</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONFLICT OF INTEREST</head><p><s>None declared.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>AUTHOR CONTRIBUTIONS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conceptualization</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Coronary stents: historical development, current status and future directions</title>
		<author>
			<persName><forename type="first">J</forename><surname>Iqbal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Serruys</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br Med Bull</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="193" to="211" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Outcomes associated with drug-eluting and bare-metal stents: a collaborative network metaanalysis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Stettler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wandel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Allemann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">370</biblScope>
			<biblScope unit="issue">9591</biblScope>
			<biblScope unit="page" from="937" to="948" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study</title>
		<author>
			<persName><forename type="first">L</forename><surname>Räber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Magro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Stefanini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1110" to="1121" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk</title>
		<author>
			<persName><forename type="first">M</forename><surname>Joner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Finn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Farb</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="193" to="202" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Stent thrombosis with secondversus first-generation drug-eluting stents in real-world percutaneous coronary intervention: analysis of 3806 consecutive procedures from a large-volume single-center prospective registry</title>
		<author>
			<persName><forename type="first">H</forename><surname>Dores</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Raposo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Teles</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Invasive Cardiol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="330" to="336" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31,379 patients</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Navarese</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kowalewski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kandzari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Open Heart</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">e000064</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">ACCF/AHA/SCAI guidelines for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the Society for Cardiovascular Angiography and Interventions</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">N</forename><surname>Levine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Bates</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Blankenship</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="issue">23</biblScope>
			<biblScope unit="page" from="2574" to="2609" />
			<date type="published" when="2011">2011. 2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Next generation drug-eluting stents: focus on bioabsorbable platforms and polymers</title>
		<author>
			<persName><forename type="first">B</forename><surname>Doyle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Holmes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med Devices (Auckl)</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="47" to="55" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Stent thrombosis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Holmes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Kereiakes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Garg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="1357" to="1365" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Stent thrombosis: incidence, predictors and new technologies</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Buchanan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Basavarajaiah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chieffo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Thrombosis</title>
		<imprint>
			<biblScope unit="volume">2012</biblScope>
			<biblScope unit="page" from="1" to="12" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Final 5-year outcomes from the Endeavor zotarolimus-eluting stent clinical trial program: comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Kandzari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Leon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Meredith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fajadet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wijns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mauri</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JACC Cardiovasc Interv</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="502" to="512" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</title>
		<author>
			<persName><forename type="first">D</forename><surname>Moher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Liberati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tetzlaff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">151</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="264" to="269" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel stent Kosten-Effektivitats trial-PROspective validation examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial</title>
		<author>
			<persName><forename type="first">C</forename><surname>Kaiser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Galatius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jeger</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="74" to="81" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: results of the randomized BIOFLOW-II trial</title>
		<author>
			<persName><forename type="first">S</forename><surname>Windecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Haude</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Neumann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circ Cardiovasc Interv</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">e001441</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Kandzari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mauri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Koolen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">390</biblScope>
			<biblScope unit="page" from="1843" to="1852" />
			<date type="published" when="2017">2017. 10105</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial</title>
		<author>
			<persName><forename type="first">C</forename><surname>Von Birgelen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Kok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Van Der Heijden</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">388</biblScope>
			<biblScope unit="page" from="2607" to="2617" />
			<date type="published" when="2016">2016. 10060</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable-polymer everolimus-eluting stent for percutaneous coronary revascularization: 2-year results of the BIOSCIENCE trial</title>
		<author>
			<persName><forename type="first">R</forename><surname>Zbinden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Piccolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Heg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Heart Assoc</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">e003255</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimuseluting coronary stent system: the CENTURY II (clinical evaluation of new Terumo drug-eluting coronary stent system in the treatment of patients with coronary artery disease) trial</title>
		<author>
			<persName><forename type="first">S</forename><surname>Saito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Valdes-Chavarri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Richardt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="issue">30</biblScope>
			<biblScope unit="page" from="2021" to="2031" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with coronary artery disease: final 5-year report from the COMPARE II trial (abluminal biodegradable polymer biolimuseluting stent versus durable polymer everolimus-eluting stent)</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Vlachojannis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Smits</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Hofma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JACC Cardiovasc Interv</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1215" to="1221" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Randomised study of a bioabsorbable polymer-coated sirolimus-eluting stent: results of the DESSOLVE II trial</title>
		<author>
			<persName><forename type="first">W</forename><surname>Wijns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Vrolix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Verheye</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">EuroIntervention</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1383" to="1390" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Comparison of everolimus-and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds</title>
		<author>
			<persName><forename type="first">S</forename><surname>Puricel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Arroyo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Corpataux</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="791" to="801" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimuseluting stent</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">T</forename><surname>Meredith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Verheye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">J</forename><surname>Weissman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">EuroIntervention</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="308" to="315" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II randomized trial</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Kereiakes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">T</forename><surname>Meredith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Windecker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circ Cardiovasc Interv</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">e002372</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Five-year outcomes from a trial of three limus-eluting stents with different polymer coating in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kufner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Byrne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Valenskini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">EuroIntervention</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1372" to="1379" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Comparison of biolimus A9-eluting (Nobori) and everolimus-eluting (Promus element) stents in patients with de novo native long coronary artery lesions: a randomized long drug-eluting stent V trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circ Cardiovasc Interv</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="322" to="329" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Five-year outcome of a randomized trial comparing second generation drug-eluting stents using either biodegradable polymer or durable polymer: the NOBORI biolimus-eluting versus XIENCE/ PROMUS everolimus-eluting stent trial (NEXT)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Natsuaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kozuma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Morimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kadota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Muramatsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nakagawa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">EuroIntervention</title>
		<imprint>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Randomized multicenter trial investigating angiographic outcomes of hybrid sirolimus-eluting stents with biodegradable polymer compared with everolimus-eluting stents with durable polymer in chronic total occlusions: the PRISON IV trial</title>
		<author>
			<persName><forename type="first">K</forename><surname>Teeuwen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Van Der Schaaf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Adriaenssens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JACC Cardiovasc Interv</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="133" to="143" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">The twelve-month outcome of biolimus-eluting stent with biodegradable polymer compared with an everolimus-eluting stent with durable polymer</title>
		<author>
			<persName><forename type="first">A</forename><surname>Separham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Sohrabi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Aslanabadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ghaffari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cardiovasc Thorac Res</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="113" to="116" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Comparison of durable-polymer zotarolimus-eluting and biodegradable-polymer biolimuseluting coronary stents in patients with coronary artery disease: 3-year clinical outcomes in the randomized SORT OUT VI trial</title>
		<author>
			<persName><forename type="first">B</forename><surname>Raungaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">H</forename><surname>Christiansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">E</forename><surname>Bøtker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JACC Cardiovasc Interv</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="255" to="264" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Lansky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">EuroIntervention</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="75" to="83" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results</title>
		<author>
			<persName><forename type="first">B</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Han</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chin Med J (Engl)</title>
		<imprint>
			<biblScope unit="volume">124</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="811" to="816" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Measuring inconsistency in meta-analyses</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Higgins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Deeks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">327</biblScope>
			<biblScope unit="issue">7414</biblScope>
			<biblScope unit="page" from="557" to="560" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Clinical end points in coronary stent trials: a case for standardized definitions</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Cutlip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Windecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mehran</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="2344" to="2351" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Systematic reviews in health care: investigating and dealing with publication and other biases in metaanalysis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Sterne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Egger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">323</biblScope>
			<biblScope unit="issue">7304</biblScope>
			<biblScope unit="page" from="101" to="105" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">The Cochrane Collaboration&apos;s tool for assessing risk of bias in randomised trials</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Higgins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Gøtzsche</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">343</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">5928</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Second-generation drug-eluting stents. Moving the field forward</title>
		<author>
			<persName><forename type="first">F</forename><surname>Alfonso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fernandez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="26" to="29" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Coronary stent technology: a narrative review</title>
		<author>
			<persName><forename type="first">D</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Jepson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med J Aust</title>
		<imprint>
			<biblScope unit="volume">205</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="277" to="281" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Biodegradable polymer drug-eluting stents versus first-generation durable polymer drug-eluting stents</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Bundhun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pursun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Medicine</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="issue">47</biblScope>
			<biblScope unit="page">e8878</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Biocompatability of biodegradable and nonbiodegradable polymer-coated stents implanted in porcine peripheral arteries</title>
		<author>
			<persName><forename type="first">De</forename><surname>Scheerder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Wilczek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Verbeken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cardiovasc Intervent Radiol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="227" to="232" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries</title>
		<author>
			<persName><forename type="first">W</forename><surname>Van Der Giessen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lincoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Schwartz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1690" to="1697" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<monogr>
		<title level="m" type="main">Boston Scientific receives FDA approval for SYNERGY bioabsorbable polymer drug-eluting stent system: new category of drugeluting stent approved for U.S. patients</title>
		<author>
			<persName><forename type="first">T</forename><surname>Backes</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2015">2015</date>
			<pubPlace>Boston Scientific; Marlborough, MA, USA</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Adverse cardiovascular events associated with biodegradable polymer drug-eluting stents and durable polymer everolimus-eluting stents: a systematic review and meta-analysis of 10 randomized controlled trials</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">K</forename><surname>Bundhun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Janoo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Yanamala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Medicine</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="issue">28</biblScope>
			<biblScope unit="page">e7510</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Comparable clinical safety and efficacy of biodegradable versus durable polymer paclitaxel eluting stents despite shorter dual antiplatelet therapy: insights from a multicenter, propensity score-matched registry</title>
		<author>
			<persName><forename type="first">P</forename><surname>Buszman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Orlik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Trela</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Catheter Cardiovasc Interv</title>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="e155" to="e162" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Optimal duration of dual antiplatelet therapy after drug eluting stent implantation: a network meta-analysis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Gajulapalli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Pattanshetty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Athappan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Anatol J Cardiol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="251" to="260" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<monogr>
		<title level="m" type="main">ACC/AHA guidelines focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of</title>
		<author>
			<persName><forename type="first">G</forename><surname>Levine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Bates</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bittl</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Heart Association task force on clinical practice guidelines</title>
		<author>
			<persName><surname>Cardiology/American</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1082" to="1115" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
